Gastrointestinal Stromal Tumor Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Gastrointestinal Stromal Tumor pipeline constitutes 25+ key companies continuously working towards developing 28+ Gastrointestinal Stromal Tumor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Gastrointestinal Stromal Tumor Overview
Gastrointestinal stromal tumor (GIST) is rare cancer affecting the digestive tract or nearby structures within the abdomen. Itis a sarcoma that arises either from cells called interstitial cells of Cajal (ICCs) or from less differentiated stem cells or precursor cells that can develop into ICCs.

"Gastrointestinal Stromal Tumor Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gastrointestinal Stromal Tumor Market.

The Gastrointestinal Stromal Tumor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Gastrointestinal Stromal Tumor Pipeline Report: https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Gastrointestinal Stromal Tumor treatment therapies with a considerable amount of success over the years. Gastrointestinal Stromal Tumor Key players such as - IDRx, Inc., Theseus Pharmaceuticals, Novartis, Arog Pharmaceuticals, Inc., Jiangsu HengRui Medicine Co., Ltd., Cogent Biosciences, Inc., CStone Pharmaceuticals, Amgen, Cogent Biosciences, Inc., Plexxikon, Zai Lab (Shanghai) Co., Ltd., Daiichi Sankyo, Inc., Jiangsu HengRui Medicine Co., Ltd., AB Science, Novartis Pharmaceuticals, Pfizer, Bayer, and others, are developing therapies for the Gastrointestinal Stromal Tumor treatment
• Gastrointestinal Stromal Tumor Emerging therapies such as - IDRX-42, THE-630, PDR001, Crenolanib, Famitinib, CGT9486, CS3007 (BLU-285), AMG 706, PLX9486, Pexidartinib, DCC-2618, DS-6157a, Famitinib capsules, Masitinib, Nilotinib, sunitinib malate, Regorafenib, and others are expected to have a significant impact on the Gastrointestinal Stromal Tumor market in the coming years.
• In January 2022, Cogent Biosciences, Inc. initiated a Phase III open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 426 patients
• In June 2022, Immunicm AB was granted an Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for ilixadencel in the treatment of Gastrointestinal Stromal Tumors (GIST)
• In June 2022, Ascentage Pharma announced the latest results from a Phase Ib/II study of the third-generation tyrosine kinase inhibitor (TKI) olverembatinib (HQP1351) in patients with metastatic gastrointestinal stromal tumor (GIST) who were resistant to or failed prior TKI treatment. The company reported the promising antitumor activity of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor- (TKI-) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST)
• In January 2022, Theseus Pharmaceuticals, announced that the first patient has been treated in the Phase I portion of Theseus' ongoing Phase I/II study to evaluate lead candidate, THE-630, in patients with advanced gastrointestinal stromal tumors (GIST). The initial data is expected in 1H 2023. In February 2022, US Food and Drug Administration granted orphan drug designation (ODD) to the company's lead candidate THE-630, for the treatment of patients with advanced gastrointestinal stromal tumors (GIST)
• In August 2021, FDA Granted Orphan Drug Designation for bezuclastinib/CGT9486 in GIST (Gastrointestinal Stromal Tumors).FDA granted orphan drug designation for bezuclastinib for the treatment of GIST with an estimated 4,000 to 6,000 GIST cases diagnosed annually in the United States

Route of Administration
Gastrointestinal Stromal Tumor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Gastrointestinal Stromal Tumor Pipeline Therapeutics Assessment
• Gastrointestinal Stromal Tumor Assessment by Product Type
• Gastrointestinal Stromal Tumor By Stage and Product Type
• Gastrointestinal Stromal Tumor Assessment by Route of Administration
• Gastrointestinal Stromal Tumor By Stage and Route of Administration
• Gastrointestinal Stromal Tumor Assessment by Molecule Type
• Gastrointestinal Stromal Tumor by Stage and Molecule Type

DelveInsight's Gastrointestinal Stromal Tumor Report covers around 28+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Gastrointestinal Stromal Tumor Therapeutics Market include:
Key companies developing therapies for Gastrointestinal Stromal Tumor are - jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, AB Science, Immunicm AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, Ascentage Pharma, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others.

Emerging Gastrointestinal Stromal Tumor Drugs Under Different Phases of Clinical Development Include:
• IDRX-42: IDRx, Inc.
• THE-630: Theseus Pharmaceuticals
• PDR001: Novartis
• Crenolanib: Arog Pharmaceuticals, Inc.
• Famitinib: Jiangsu HengRui Medicine Co., Ltd.
• CGT9486: Cogent Biosciences, Inc.
• CS3007 (BLU-285): CStone Pharmaceuticals
• AMG 706: Amgen
• DS 6157: Daiichi Sankyo Company
• PLX9486: Cogent Biosciences, Inc.
• Pexidartinib: Plexxikon
• DCC-2618: Zai Lab (Shanghai) Co., Ltd.
• DS-6157a: Daiichi Sankyo, Inc.
• Famitinib capsules: Jiangsu HengRui Medicine Co., Ltd.
• Masitinib: AB Science
• Nilotinib: Novartis Pharmaceuticals
• sunitinib malate: Pfizer
• Regorafenib: Bayer

Get a Free Sample PDF Report to know more about Gastrointestinal Stromal Tumor Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Gastrointestinal Stromal Tumor Pipeline Analysis:
The Gastrointestinal Stromal Tumor pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Gastrointestinal Stromal Tumor with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastrointestinal Stromal Tumor Treatment.
Gastrointestinal Stromal Tumor key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Gastrointestinal Stromal Tumor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastrointestinal Stromal Tumor market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Gastrointestinal Stromal Tumor product details are provided in the report. Download the Gastrointestinal Stromal Tumor pipeline report to learn more about the emerging Gastrointestinal Stromal Tumor therapies at:
https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Gastrointestinal Stromal Tumor Pipeline Market Drivers
• Increasing prevalence of digestive disorders
• Increasing investment of biotechnology and pharmaceutical industries in research and development Availability of funds is likely to drive the growth of the Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor Pipeline Market Barriers
• Higher cost associated with the treatment procedure and hence, this is a major fact that might be responsible for slowing the market growth
• Reimbursement Policies

Scope of Gastrointestinal Stromal Tumor Pipeline Drug Insight
• Coverage: Global
• Key Gastrointestinal Stromal Tumor Companies: IDRx, Inc., Theseus Pharmaceuticals, Novartis, Arog Pharmaceuticals, Inc., Jiangsu HengRui Medicine Co., Ltd., Cogent Biosciences, Inc., CStone Pharmaceuticals, Amgen, Cogent Biosciences, Inc., Plexxikon, Zai Lab (Shanghai) Co., Ltd., Daiichi Sankyo, Inc., Jiangsu HengRui Medicine Co., Ltd., AB Science, Novartis Pharmaceuticals, Pfizer, Bayer, and others
• Key Gastrointestinal Stromal Tumor Therapies: IDRX-42, THE-630, PDR001, Crenolanib, Famitinib, CGT9486, CS3007 (BLU-285), AMG 706, PLX9486, Pexidartinib, DCC-2618, DS-6157a, Famitinib capsules, Masitinib, Nilotinib, sunitinib malate, Regorafenib, and others
• Gastrointestinal Stromal Tumor Therapeutic Assessment: Gastrointestinal Stromal Tumor current marketed and Gastrointestinal Stromal Tumor emerging therapies
• Gastrointestinal Stromal Tumor Market Dynamics: Gastrointestinal Stromal Tumor market drivers and Gastrointestinal Stromal Tumor market barriers

Request for Sample PDF Report for Gastrointestinal Stromal Tumor Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Gastrointestinal Stromal Tumor Report Introduction
2 Gastrointestinal Stromal Tumor Executive Summary
3 Gastrointestinal Stromal Tumor Overview
4 Gastrointestinal Stromal Tumor- Analytical Perspective In-depth Commercial Assessment
5 Gastrointestinal Stromal Tumor Pipeline Therapeutics
6 Gastrointestinal Stromal Tumor Late Stage Products (Phase II/III)
7 Gastrointestinal Stromal Tumor Mid Stage Products (Phase II)
8 Gastrointestinal Stromal Tumor Early Stage Products (Phase I)
9 Gastrointestinal Stromal Tumor Preclinical Stage Products
10 Gastrointestinal Stromal Tumor Therapeutics Assessment
11 Gastrointestinal Stromal Tumor Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Gastrointestinal Stromal Tumor Key Companies
14 Gastrointestinal Stromal Tumor Key Products
15 Gastrointestinal Stromal Tumor Unmet Needs
16 Gastrointestinal Stromal Tumor Market Drivers and Barriers
17 Gastrointestinal Stromal Tumor Future Perspectives and Conclusion
18 Gastrointestinal Stromal Tumor Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Gastrointestinal Stromal Tumor drugs and therapies- https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:

Gastrointestinal Stromal Tumor Market https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Gastrointestinal Stromal Tumor-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Gastrointestinal Stromal Tumor Epidemiology https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Gastrointestinal Stromal Tumor Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.